Compare NPKI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | VIR |
|---|---|---|
| Founded | 1932 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2019 |
| Metric | NPKI | VIR |
|---|---|---|
| Price | $14.39 | $9.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.17 | ★ $29.30 |
| AVG Volume (30 Days) | 619.9K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $26.96 | N/A |
| Revenue Next Year | $13.16 | $131.58 |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.76 | $4.16 |
| 52 Week High | $15.85 | $10.91 |
| Indicator | NPKI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 62.52 |
| Support Level | $13.53 | $4.88 |
| Resistance Level | $14.58 | N/A |
| Average True Range (ATR) | 0.70 | 0.58 |
| MACD | -0.03 | 0.16 |
| Stochastic Oscillator | 40.23 | 51.86 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.